Pricing Log in Create free account
Wednesday 4 November 2026 Export CAPR’s income statement to Excel — free account

Capricor Therapeutics, Inc.

CAPR Healthcare Biotechnology

Capricor Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $22.3 million, down 11.5% from fiscal 2023.

Revenue
−7.92%
EPS
−22.8%
Free cash flow
−72.9%

Quarter to June 2026, against a year earlier

8.89 0.65 +7.89%
Market cap
$479.1M
P/E
0.0×
Fwd P/E
−13.2×
Dividend yield
—
F-score
4/9
Altman Z
10.32
Beneish M
−2.61
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 8.37
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — 3 1 2 4 — — — — —
Insider Ownership 9.11%

Capital & Financial Ratios $m

Size
Market Cap 479.07
Revenue ttm 22.27
Net income ttm (129.42)
Free cash flow ttm 130.91
Net debt Q (237.93)
Valuation
P/E 0.00
Forward P/E (13.20) (negative: loss-making)
Price / sales 21.17 (above 10: high)
Forward P/S Powerpack
Price / FCF 3.60
Price / book 1.92
Financial health
Current ratio Q 7.35 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (14.32)
Growth
Revenue growth Q −7.92% (below 0%: shrinking)
Operating income growth Q −54.94% (below 0%: shrinking)
EPS, this year +33.05% (at or above 15%: strong)
EPS, next year A +3.28%
Revenue, next year A −97.35% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +50.75% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 11.1×, against a ten-year median of 20.0×; over the ten years it ranged from 0.0× in 2026 to 462× in 2021.
P/S against its own 10 years 59.12%
10-year low 10-year high
P/B against its own 10 years 7.51%
10-year low 10-year high
EV/Sales against its own 10 years 23.32%
10-year low 10-year high
EV/FCF against its own 10 years 12.01%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 39 152 318 238
Receivables 10 10 0 —
Inventory — — — —
Other — — — —
51 163 323 242
2023 2024 2025 Q'26
Payables 6 3 2 3
ST’ Debt — — — —
Other — — 6 —
31 21 36 33

Compound Annual Growth %

10y 5y 3y
Sales 16.62% 85.83% 349.69%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% 61.08% 196.04%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.58 Actual −0.70

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.54 −0.54 Met by 0.00
Q4 FY25 −0.51 −0.62 Miss by 0.11
Q1 FY26 −0.55 −0.59 Miss by 0.04
Q2 FY26 −0.58 −0.70 Miss by 0.12
Q3 FY26 −0.61 — Reports 9 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.59) (0.70) — — —
’25 (0.53) (0.57) (0.54) (0.62) (2.26)
’24 (0.31) (0.35) (0.38) (0.16) (1.15)
’23 (0.31) (0.29) (0.25) (0.02) (0.83)
’22 (0.32) (0.29) (0.26) (0.31) (1.18)
’21 (0.23) (0.21) (0.17) (0.26) (0.87)
’20 (0.30) (0.23) (0.20) (0.21) (0.88)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’24 5 4 2 11 22
’23 3 4 6 12 25
’22 — — 2 1 3
’21 0 0 — 0 0
’20 0 0 0 0 0
’19 0 0 0 0 1
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (29) (31) — — —
’25 (6) (20) (20) (24) (70)
’24 (1) (12) (12) (15) (40)
’23 4 (9) (9) (12) (26)
’22 24 (7) (6) (7) 5
’21 (3) (5) (3) (6) (17)
’20 (1) (2) (3) (4) (10)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (40) (37) — — —
’25 (8) (22) (24) 232 179
’24 (2) (12) (12) 78 52
’23 4 (10) (9) (12) (28)
’22 23 (7) (7) (8) 2
’21 (3) (5) (4) (6) (18)
’20 (1) (2) (3) (4) (11)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 4 3 2 1 0 0 3 25 22 — 22 +23.9% 56 57 145 +61.1%
Gross margin, % 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 — 100.00 0.0 pt
EBT (19) 2 (15) (8) (14) (20) (29) (22) (40) (105) (129) +21.1%
EBT margin, % (470.33) 91.19 (908.88) (760.38) (4,401.22) (8,175.79) (1,137.35) (88.52) (181.70) 0.00 0.00 +470.3 pt
Net income (19) 2 (15) (8) (14) (20) (29) (22) (40) (105) (129) +21.1%
Per share, $
Per share, $ Revenue 2.16 1.15 0.57 0.27 0.02 0.01 0.10 0.94 0.63 0.00 0.00 n/m
Earnings (10.10) 1.00 (5.20) (2.06) (0.88) (0.87) (1.18) (0.83) (1.15) (2.26) (2.45) (15.3%)
Cash flow (7.79) (6.14) (4.71) (1.84) (0.65) (0.73) 0.20 (0.96) (1.14) (1.50) (1.80) (16.7%)
Capex (0.10) (0.01) 7.71 0.81 (0.04) (0.05) (0.14) (0.08) 2.62 5.35 4.06 n/m
Free cash flow (7.90) (6.15) 3.00 (1.03) (0.68) (0.78) 0.06 (1.03) 1.48 3.85 2.26 n/m
Book value (2.16) 4.84 1.57 1.84 1.81 1.36 0.48 0.84 4.13 6.58 4.25 n/m
Shares, m 2 2 3 4 16 23 25 27 35 46 52 +43.0%
Valuation, ×
Valuation, × P/E 0.00 52.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 — 0.00 5.8
P/S 11.83 13.66 7.21 4.73 172.12 223.49 34.30 5.45 21.82 — 21.17 55.0
P/B 0.00 3.24 2.61 0.69 1.89 2.16 8.02 6.07 3.34 — 1.92 3.1
EV/Sales 10.92 18.60 19.49 12.33 112.70 155.13 24.42 4.44 15.66 — 11.13 41.5
EV/FCF (2.98) (3.48) 3.69 0.65 (4.60) (2.61) 43.23 (4.04) 6.67 — 1.89 4.1
Cash, $m
Cash, $m Operating cash flow (14) (14) (14) (7) (10) (17) 5 (26) (40) (70) (104) +19.1%
Capex 0 0 23 3 (1) (1) (3) (2) 92 249 235 n/m
Free cash flow (15) (14) 9 (4) (11) (18) 2 (28) 52 179 131 n/m
Balance, $m
Balance, $m Working capital 13 14 7 10 31 32 19 20 142 287 209 +40.8%
Net debt (4) (11) (4) (7) (33) (35) (41) (39) (152) (318) (238) +64.4%
Shareholders’ equity (4) 11 5 7 28 31 12 23 145 306 246 n/m
Returns, %
Returns, % ROA (108.03) 13.89 (119.05) (75.06) (59.73) (52.73) (63.48) (40.96) (35.31) (39.91) (51.53) +68.1 pt
ROIC 0.00 0.00 (2,130.18) (1,463.42) 0.00 0.00 0.00 0.00 0.00 0.00 (1,019.73) 0.0 pt
ROE 747.04 67.32 (191.78) (133.42) (77.95) (67.23) (134.49) (129.63) (48.16) (46.56) (73.70) (793.6) pt
People
People Employees 40 40 22 16 26 48 74 102 160 231 — +21.5%
Revenue/emp, $m 0.10 0.07 0.08 0.06 0.01 0.01 0.03 0.25 0.14 0.00 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2024 · latest quarter Dec 2024

Capricor Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CAPR Capricor Therapeutics, Inc. $479.1M — (loss-making) — (loss-making) −7.92% (below 0%: shrinking) n/m −72.88% (below 0%: shrinking) 100.00% 0.00%
MNPR Monopar Therapeutics Inc. $469.1M — (loss-making) — — n/m −201.41% (below 0%: shrinking) — 0.00% Compare
RLMD Relmada Therapeutics, Inc. $455.5M — (loss-making) — — n/m −50.06% (below 0%: shrinking) 0.00% 0.00% Compare
YDES YD Bio Limited $453.0M — — — — — — — Compare
EPRX Eupraxia Pharmaceuticals Inc. $447.3M — (loss-making) — — n/m −56.41% (below 0%: shrinking) — 0.00% Compare
CRMD CorMedix Inc $433.4M 2.3× 11.5× +156.52% (above 0%: growing) +13.79% (above 0%: growing) +185.90% (above 0%: growing) 75.66% 42.10% Compare
PRTCY PureTech Health PLC Sponsored ADR $424.0M — (loss-making) — (loss-making) −44.60% (below 0%: shrinking) +66.43% (above 0%: growing) +19.27% (above 0%: growing) 2.83% 0.00% Compare
PRTA Prothena Corporation plc $421.5M — (loss-making) 71.4× −77.15% (below 0%: shrinking) n/m +44.64% (above 0%: growing) 100.00% (2,089.21%) Compare
ASMB Assembly Biosciences, Inc. $405.6M — (loss-making) — (loss-making) +38.94% (above 0%: growing) n/m +7.58% (above 0%: growing) 100.00% (47.44%) Compare
Median of peers $440.4M — — −2.83% — +7.58% 75.66% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 10 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 3.52m 7.23m 748.00
2024 1.54m 5.11m 358.00
2023 774.30k 1.15m 127.00

Ownership

Directors and executive officers, together 9.20%
Nippon Shinyaku Co., Ltd. 11.90%
Suvretta Capital Management, LLC 6.00%
Tang Capital Management, LLC 5.90%
BlackRock, Inc. 5.10%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Capricor Therapeutics, Inc. (CAPR) Latest News

3 Nov

Impact 4 · · Stocktwits

1 Nov

Impact 4 · · Stocktwits

21 Oct

Impact 4 · · Stocktwits

7 Oct

Impact 4 · · Stocktwits
Impact 4 · · MarketBeat

5 Oct

Impact 4 · · Stocktwits
Impact 4 · · GlobeNewswire

30 Sep

Impact 4 · · Stocktwits

29 Sep

Impact 4 · · Stocktwits

23 Sep

Impact 4 · · Simply Wall St.

7 Sep

Impact 4 ·

4 Sep

Impact 4 ·

1 Sep

Impact 3 · · InvestorsHub
Impact 3 · · Stocktwits

27 Aug

Impact 4 ·

24 Aug

Impact 4 · · Stocktwits
Impact 4 · · Stocktwits
Impact 4 ·
Impact 3 · · InvestorsHub
Impact 3 · · biopharmadive.com

21 Aug

Impact 4 · · Stocktwits
Impact 4 · · Stocktwits
Impact 3 ·
Impact 3 ·

20 Aug

Impact 4 · · The Motley Fool transcript

19 Aug

Impact 4 ·

15 Aug

Impact 4 ·
Impact 3 · · Moby transcript

14 Aug

Impact 4 · · Stocktwits
Impact 4 · · biopharmadive.com
stockrow.com/CAPR · Data as of Dec 31, 2024 · For information only; not investment advice. · © 2026 stockrow.com